INOVIQ Ltd (ASX:IIQ)

Market Cap	44.65M
Revenue (ttm)	1.82M
Net Income (ttm)	-6.93M
Shares Out	111.63M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	37,633
Average Volume	81,457
Open	0.3950
Previous Close	0.4000
Day's Range	0.3950 - 0.4000
52-Week Range	0.3450 - 0.6900
Beta	1.81
RSI	50.74
Earnings Date	Aug 27, 2025

About INOVIQ

INOVIQ Ltd develops and commercializes diagnostic and exosome‐based products to enhance the diagnosis and treatment of cancer and other diseases in Australia and the United States. It offers hTERT ICC test, an immunocytochemistry test used as an adjunct to urine cytology testing for bladder cancer; and EXO-NET, an EV isolation tool for biomarker discovery and diagnostic development. It offers non-invasive, diagnostics using its proprietary exosome develops technologies for improved screening, diagnosis, treatment selection and monitoring of can...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2016
• Employees: 15
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: IIQ

Financial Performance

In 2025, INOVIQ's revenue was 1.82 million, an increase of 16.25% compared to the previous year's 1.56 million. Losses were -6.93 million, 5.77% more than in 2024.